European Approval For Roxadustat Is Silver Lining For FibroGen
But Will Not Head Off Restructuring
The EU approval is good news for FibroGen and marketing partner Astellas, but was expected, and still leaves it pondering its future after FDA knock-back.
You may also be interested in...
After US Woes, Akebia Celebrates EU Nod For Vafseo
The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold as Vafseo.
GSK Confident Its ‘Last Drug Standing’ In Anemia Class Can Gain US Panel Backing
GSK could have the US market to itself if it can convince the expert panel of daprodustat’s safety, as rivals have fallen by the wayside.
Akebia Could Face Long, Costly Effort To Overcome Vadadustat CRL
The US FDA turned down approval for vadadustat in chronic kidney disease anemia, in a complete response letter that unexpectedly included the dialysis-dependent indication.